Orchid completes sale of injectables business to Hospira
This article was originally published in Scrip
Orchid Chemicals and Pharmaceuticals has completed the sale and transfer of its generic injectable finished dosage business to Hospira Inc's Indian subsidiary. The transaction included Orchid’s betalactam injectable antibiotics manufacturing complex and formulations R&D facility at Irungattukottai, Chennai, and its generic injectable product portfolio and pipeline. About 450 Orchid employees are also expected to move to Hospira. Last December, Hospira had Orchid's injectables business for about $400 million, giving it a direct presence in India as also access to cost-effective production facilities for generic injectables, among other gains (scripnews.com, 17 December 2009).
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.